Bioqual, Inc. Stock Other OTC
Equities
BIOQ
US09065J1016
Biotechnology & Medical Research
Sales 2022 | 66.15M 90.75M | Sales 2023 | 62.66M 85.97M | Capitalization | 67.98M 93.26M |
---|---|---|---|---|---|
Net income 2022 | 5M 6.86M | Net income 2023 | - 0 | EV / Sales 2022 | 1.2 x |
Net Debt 2022 | 16.54M 22.69M | Net Debt 2023 | 11.33M 15.54M | EV / Sales 2023 | 1.27 x |
P/E ratio 2022 |
11.9
x | P/E ratio 2023 |
81.7
x | Employees | - |
Yield 2022 |
1.43% | Yield 2023 |
0.66% | Free-Float | 55.92% |
Managers | Title | Age | Since |
---|---|---|---|
Mark G. Lewis
CEO | Chief Executive Officer | 69 | 03-07-31 |
Charles C Kirk
DFI | Director of Finance/CFO | - | - |
Chief Tech/Sci/R&D Officer | - | 22-05-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 87 | 14-12-31 | |
Mark G. Lewis
CEO | Chief Executive Officer | 69 | 03-07-31 |
Director/Board Member | - | - |
1st Jan change | Capi. | |
---|---|---|
+0.67% | 42.4B | |
+46.85% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |